Silvia Novello
Giorgio Scagliotti
Peter Goodwin interviews Silvia Novello, and Giorgio Scagliotti from the University of Turin about harnessing insulin-like growth factor receptor inhibition in a phase II study which has shown clinical activity of figitumumab at least as significant as inhibitors of other growth factors already being used in cancer.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
This entry was posted in Oncology. Bookmark the permalink. Post a comment or leave a trackback: Trackback URL.